<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03634189</url>
  </required_header>
  <id_info>
    <org_study_id>CAPITAL-AC</org_study_id>
    <nct_id>NCT03634189</nct_id>
  </id_info>
  <brief_title>Cannabidiol in Patients With Heart Failure Failure in AHA/ACC Stages A-C</brief_title>
  <acronym>CAPITAL-AC</acronym>
  <official_title>Phase I, Single Center, Open-label Study of Cannabidiol in Patients With Heart Failure in AHA/ACC Stages A-C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cannabidiol in heart failure
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related serious adverse events and events of interest as assessed by MedDRA v5.1</measure>
    <time_frame>6 months</time_frame>
    <description>We will assess the safety of CBD in patients with HF ACC/AHA stages A-C based on the incidence of events of interest and serious adverse events. This assessment will be performed at each on-site visit.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>HF- ACC/AHA stage A-C + CBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HF stages A-C + Cannabidiol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>Patients with ACC/AHA stage A-C will receive 5 mg/kg to a maximum tolerated dose of 25 mg/kg PO BID of Cannabidiol</description>
    <arm_group_label>HF- ACC/AHA stage A-C + CBD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Men and women (women not pregnant neither in lactation period) between 30 to 75
             years-old

          -  Patients with stage A-C of the American College of Cardiology/American Heart
             Association classification

          -  Patients with GDMT and clinical stability within four weeks

          -  Diagnosis of ischemic or non-ischemic dilated cardiomyopathy

          -  Participants should sign an informed consent form (ICF) form personally

        Exclusion criteria

          -  Severe primary valvular cardiomyopathy or valvular prosthesis (mechanical or
             bio-valve)

          -  History of heart transplant surgery, cardiomyoplasty, left ventricular reduction
             surgery, valvuloplasty, implantation of a ventricle assist device and surgical cardiac
             congenital defect correction

          -  Implantable cardioverter defibrillator within the last three months

          -  Acute coronary syndromes that required pharmacological or mechanical reperfusion or
             medical treatment, within 30 days before selection

          -  Percutaneous coronary intervention within 30 days prior to selection

          -  Women who are pregnant, or of childbearing potential and are not practicing an
             effective means of birth control

          -  Untreated thyroid disease

          -  Hepatorenal syndrome

          -  History of seizures

          -  Hemoglobin: &lt; 8.5 gm/dL

          -  WBC count lower than 3000/mm3

          -  Platelets: &lt;100,000/mm

          -  AST or ALT &gt;2.5 × upper limit of normal (ULN) unless related to primary disease

          -  Treatment with any investigational agent within 4 weeks of screening or 5 half-lives
             of the investigational drug (whichever is longer)

          -  Active cancer of any etiology

          -  History of psychiatric disorder (depression or PHQ-9 ≥ 10 points , bipolar syndrome,
             schizophrenia) or suicide attempt.

          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or that may affect the
             interpretation of the results or render the patient at high risk from treatment
             complications

          -  Fertile female participants not applying any approved duel anti-contraceptive method

          -  Inability to comply/assist with study and follow-up procedures

          -  Patients in cardiovascular rehabilitation programs

          -  Any person who is not able to give adequate ICF

        Elimination criteria

          -  Progression of heart failure stage according to the American College of
             Cardiology/American Heart Association classification, since the initiation of the
             study.

          -  ALT or AST &gt;3x normal values with a total bilirubin ≥ 2x normal value.

          -  Any degree of depression at any stage of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guillermo Torre-Amione, MD, PhD</last_name>
    <phone>+52-81-8888-0500</phone>
    <email>guillermo.torre@itesm.mx</email>
  </overall_contact>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud</investigator_affiliation>
    <investigator_full_name>David Rodriguez</investigator_full_name>
    <investigator_title>Clinical Research Coordinator</investigator_title>
  </responsible_party>
  <keyword>Cannabidiol</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>AHA/ACC stage A-C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidiolex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

